Under construction – not a live service
Sign in
Taking people in UkrainePhase 1

Tests SGR-1505 in adults with B-cell lymphoma and related blood cancers

Tests the drug SGR-1505 for safety in adults with B-cell blood cancers.

Key facts

Who runs it
Schrödinger, Inc.
Where
Kyiv, UkraineSee the siteAlso in 7 other countries, 36 sites
Registry title
Study of SGR-1505 in Mature B-Cell Neoplasms
Status
Recruiting
Phase
Phase 1
People taking part
98 people, planned
Started
10 Apr 2023
Expected to end
Nov 2027
Type of study
Interventional
Treatments tested
  • SGR-1505
Record updated
13 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a confirmed mature B-cell cancer that can be measured and needs treatment. It tests the safety and dose of SGR-1505.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Mature B-cell cancer (history confirmed by tissue or cell tests) with measurable or detectable disease that meets criteria for starting treatment.

Main reasons for not taking part

  • Needs immediate treatment to reduce tumour size (unless no other treatment choice with potential benefit remains)
  • Another invasive cancer in the last 2 years
  • Known allergy to SGR-1505 or its other ingredients
  • Symptomatic or active disease in the brain or spinal cord (CNS)
  • Other illness or finding that would raise the risk of an investigational drug

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy
  • Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Life expectancy ≥ 12 weeks

Who cannot take part

  • The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit)
  • Subject has previous invasive malignancy in the last 2 years
  • Subject has a known allergy to SGR-1505 or excipients of SGR-1505
  • Subject has symptomatic or active CNS involvement of disease
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug

Where in Ukraine

Also in 7 other countries, 36 sites

  • ARENSIA Research Clinic at Harmony Health ClinicKyiv, UkraineContact: Study PhysicianTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

The group in the trial

  • Dose EscalationTreatment being tested

    Up to 9 dose levels in total will be evaluated across two dosing schedules. Eligible patients will be assigned to a dose level cohort according to an accelerated titration design that will transition to a traditional 3+3 dose escalation.

    Treatment: SGR-1505

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies
Plain-language title
Tests SGR-1505 in adults with B-cell lymphoma and related blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 February 2026